Archive for the ‘Treatment’ Category

Alpha-Gal, The Tick Was Always a Needle

https://unfiltered.doctorschierling.com/p/alpha-gal-part-ii-the-tick-was-always?

Alpha-Gal, Part II: The Tick Was Always a Needle

The one question I left standing in Part I — if it was the shots, why the tick at all? The scientific literature answers it in one word. Three questions that collapse the tick story from the inside.

Russell Schierling

Jul 10, 2026

For my children and grandchildren…

In Part I, I built a fence. On one side, I put everything solid — Richet’s Nobel Prize, the route problem, the Japanese gelatin admission, the billing codes, and my own Amish patient base, covered in ticks, completely unvaccinated, and, at least as far as I can ascertain, free of alpha-gal — with a single imported exception I’ll come back to shortly. On the other side, I put my suspicions about a declassed clandestine program, telling you where the record stopped, and my hunches began.

Today, there will be no discussion of Fort Detrick, Plum Island, or other biolabs / bioweapon labs. There’s no need for that when answering a question that several readers asked via the comment section. Before I had finished my morning coffee…

If it’s really the shots that cause alpha-gal, then why is the tick needed at all?

I’m going to answer this by asking and answering three very specific questions from the tick research community’s own filing cabinet — CDC-funded papers and the industry-disclosed authors. From the scientists who are certain the Lone Star tick is the primary cause.

I’m going to let people far smarter than me answer these questions using their own studies…

Question One: Why Is a Tick Needed At All?

But the condition has no historical precedent. It appears in the literature at a specific moment in the late 1980s, in multiple countries simultaneously, at a time when gelatin-containing vaccines were being introduced into childhood immunization schedules worldwide. Japanese researchers documented, confirmed through intervention, and published the direct causal relationship between gelatin-containing DTaP vaccines and alpha-gal sensitization in children who had never been exposed to ticks. That evidence is in the peer-reviewed record. It has been there since 1996. -From Dr Travis Johnson’s June 2 piece in Medium (The Allergy That Shouldn’t Exist: Vaccines, Gelatin, and the Strange Origins of Alpha-Gal Syndrome)

To answer question one, it isn’t — at least not as the origin. Vaccines alone can do it — the tick isn’t required for the mechanism. But historically, before the schedule ballooned, cases clustered in tick country. And the scientific literature already told you why.

Go pull the 2021 paper from Frontiers in Cellular and Infection Microbiology that tick researchers themselves titled “Tick Saliva and the Alpha-Gal Syndrome: Finding a Needle in a Haystack”. Read that title again. A needle in a haystack. They picked the metaphor, but pointed it at the park instead of at the vial.

Let’s watch what the tick actually does and why the needle in the haystack might be apropos, but maybe not in the way the authors intended…

Another 2021 study, this one on a tick enzyme, describes the alpha-gal sugar as being — their word, not mine — “injected into humans from the lone-star tick bite”. Injected. Not eaten. Not digested. Injected — straight through the skin, past the gut and its digestive processes, and into areas where food is not supposed to be. And as I stated in Part I, this is extremely similar to the phenomenon I have referred to for over two decades as “The Leakies”. Example: (Systemic Leaky Barrier Syndrome (SLBS): A Systems-Level Framework for Chronic Disease).

Earlier studies localized the sugar to the secretory vesicles of the tick’s salivary glands — meaning it’s built to be squirted into a bite. In other words, it’s not wrong to think of ticks as syringes with eight legs — light enough to cross your skin without tripping pressure receptors, and armed with saliva loaded with painkillers, anti-inflammatories, and anticoagulants that let them latch and drink for days without ever setting off the itch that would make you look down and flick them off.

What these devilish little creatures are loading into you is galactose-alpha-1,3-galactose — alpha-gal for short; the “ose” tells you it’s a sugar, like glucose or sucrose — a bit of mammalian sweetness squirted straight under your skin. And here’s the kicker nobody thus far has answered…

When it comes to the animals the tick commonly feeds on — deer, cattle, dogs, rodents, goats, hogs, etc — alpha-gal is “endogenous”. In other words, they build it, they carry it, and their immune systems recognize it as native (“self”) so that it’s not attacked as an invader. So the best answer for why it’s in the saliva at all isn’t that it works some mechanical trick like the anticoagulants and painkillers do — it’s camouflage. Dress your spit in the host’s own sugar, and it reads as ‘self,’ letting the tick guzzle until 100X normal size, all under the immune radar. Which means the sugar is doing exactly its job on a deer. (See link for article)

_____________

**Comment**

Probably the most comprehensive article on the subject and is deserving of your time. I also highly recommend Part 1: Alpha-Gal: Why it Might Be the Shots, Not Just the Ticks. The Amish as a community due to defying government dictates, flourished during COVID as well.

The most important take-away is the fact that the Ozarks are full of deer, lone star ticks, and ‘vaccinated’ people, with the exception of the unvaccinated Amish whom are smack dab in the middle of the same area and free of AGS.

“Geography is an alibi the ‘forced vaccination community’ at large is hiding behind because ticks and the heavily vaccinated live side by side in so much of the country.” ~ Dr. Shierling

The good doctor also states he’s only come into ONE Amish person who got AGS, but that she grew up in Minnesota and received some vaccines as an infant…..

Another important take-away is that the younger the child and the larger the ‘vaccine’ dose(s), the more likely they are to develop sensitivity rather than tolerance. The Journal of the American Dental Association now quietly lists topical numbing gels, Gelfoam, prophy paste, catgut, bone graft materials — while noting manufacturers aren’t required to disclose animal-derived ingredients, as containing alpha-gal bearing excipients. This website has also posted the fact that graphene oxide was found in all three dental anesthetics tested.

For more on AGS:


Category:

Lyme, Testing, Ticks, Treatment, vaccines

The Hidden Drivers of Inflammatory Bowel Disease (Lyme Disease is One)

https://imahealth.substack.com/p/the-hidden-drivers-of-inflammatory? Video Here

The Hidden Drivers of Inflammatory Bowel Disease

Crohn’s and colitis are called genetic, autoimmune, and idiopathic. What if all three labels are wrong? A new paper tests each against current evidence.

Independent Medical Alliance

Aug 02, 2026

Host: Dr. JP Saleeby | Guest: Josh Dech

What if Crohn’s disease and ulcerative colitis are caused by more than genetics alone?

Dr. Yusuf “JP” Saleeby, IMA Senior Fellow in Functional and Integrative Medicine, and gut health specialist Josh Dech take a closer look at what may contribute to inflammatory bowel disease, also known as IBD. The two recently co-authored a new paper published in the Journal of Independent Medicine. Their conversation traces how genetics, diet, gut health, and the environment may work together to shape both diseases.

Inflammatory bowel disease affects more than 7 million people worldwide and ranks among the fastest-growing chronic diseases globally. Nearly everyone diagnosed with Crohn’s disease or ulcerative colitis hears some version of the same three things: the disease is genetic, the immune system is attacking its own tissue, and the underlying cause is unknown. Those three explanations leave two treatments on the table, drugs and surgery, and they leave a patient nothing to investigate.

A new paper in the Journal of Independent Medicine argues that all three explanations fail against current evidence. Josh Dech and Dr. JP Saleeby, its co-authors, point out that each has been contested separately in the literature for two decades without anyone testing them as a set. Taken together, they conclude, the conventional model does not hold.

What replaces it is a disease that is partially heritable, environmentally activated, and immune-mediated, and the distinction is not academic for anyone living with one. If exposures determine whether susceptibility becomes disease, exposures can be found and changed. (See link for article, research paper and video)

_____________

SUMMARY:

  • The authors found that genetics only explain about a quarter of disease risk for irritable bowel (IBD).
  • The authors argue that the autoimmune label, despite holding for decades, is based on the weakest evidence and that pathogenic transfer has never been demonstrated.
  • The serologic markers long cited as evidence for autoimmunity turn out to recognize microbial and fungal targets but are not autoantibodies in the classical sense.
  • A review of 53 meta-analyses across 71 risk factors shows the following exposures for IBD that are quantified and modifiable:
    • antibiotic exposure
    • oral contraceptives
    • breast-feeding was protective for Crohn’s and colitis
    • ultra-processed food
    • air pollution
    • psychological stress
    • mold
    • mycotoxins
  • The authors state current treatments complement but ignore the environmental exposures.
  • The authors give the following issues that should be questioned alongside a standard work-up:
    • Birth mode and feeding history
    • Early antibiotic courses, particularly before age 5
    • Water damage & mold exposure at home, work and in vehicles.
    • Adolescent diet, stressors, and infections

At this point in the article, they described a case report on a 14 year old whose Crohn’s progressed far enough that surgeons planned to remove most of his intestines & place a colostomy. Testing pointed to chronic Lyme disease and three months into treatment a repeated scope test found no lesions.

In short, they conclude the following answers for IBS: antibiotic stewardship, breastfeeding support, reducing ultra-processed food, and remediating indoor mold.

After reading the comments after the article, I would be remiss if I did not mention the ‘vaccine’ issue due to the fact they all introduce foreign substances the body recognizes as foe, priming it for later potential problems such as life-threatening allergies to many things including food, which many are also linking to Alpha Gal Syndrome (AGS), an allergy to animal products supposedly caused by ticks – with no solid proof, as well as the fact some get AGS without any known tick involvement. So while ticks play a part, they are obviously not the only ingredient required to get AGS.

Pathogenic priming was shown clearly with the COVID gene therapy injections.

For more:

Category:

Candida, diet and nutrition, Inflammation, Lyme, research, Treatment

Old Molecule, New Evidence: Chlorine Dioxide Shows Promise in 3 Veterinary Cases

https://imahealth.substack.com/p/old-molecule-new-evidence-chlorine?

Old Molecule, New Evidence: Chlorine Dioxide Shows Promise in Three Veterinary Cases

Three animals with limited options improved after treatment with chlorine dioxide. A new case series in the Journal of Independent Medicine documents what happened.

Independent Medical Alliance

May 27, 2026

The FDA calls chlorine dioxide “a dangerous bleach.” Millions of people drink low doses of it every day in treated tap water. And clinicians and veterinarians have been quietly using it for years to treat conditions that conventional medicine couldn’t resolve.

A new case series in the Journal of Independent Medicine puts clinical outcomes on the record for the first time in veterinary medicine.

Teresa Carr, a veterinarian with 30 years of clinical experience, and Mitchell Liester, MD, an adjoint assistant professor in the Department of Psychiatry at the University of Colorado School of Medicine, documented what happened when they used chlorine dioxide protocols on three animals that had run out of conventional options. A dog with suspected liver cancer. A cat with an infection that wouldn’t respond to antibiotics. A dog with a large, painful mammary tumor. All three improved.

“I began independently researching alternative therapies for patients with more complex conditions.” — Teresa Carr

📖 Read and Download the Full Paper

Chlorine Dioxide as an Adjunctive Treatment in Three Veterinary Cases: A Case Series (JIM Vol. 2, No. 3, 2026) — Authors: Teresa Carr and Mitchell Liester

What Chlorine Dioxide Is

Chlorine dioxide is a selective oxidant first synthesized in 1811. This is not the stuff you accidentally gulped at the swimming pool as a kid. It is a distinct molecule with a different mechanism of action: it selectively oxidizes specific amino acids in microbial proteins, disrupting their function and replication. That gives it broad-spectrum antimicrobial activity against bacteria, viruses, fungi, and parasites.

“Chlorine dioxide was synthesized over 200 years ago, but was primarily used as a water treatment agent. It also has broad spectrum antimicrobial activity against bacteria, viruses, fungi, and parasites.” — Mitchell Liester

Regulatory agencies have approved it for water treatment, food safety, and medical equipment sterilization. The antimicrobial properties are not in dispute. What’s been missing is formal clinical investigation.

The human data that does exist is promising. Studies have documented improved glucose control, reduced inflammation, enhanced wound healing, and activity against antibiotic-resistant pathogens. A case series showed complete resolution of treatment-refractory diabetic foot ulcers, with one patient achieving sustained medication-free glycemic control for three years.

The Safety Question

The FDA labeled chlorine dioxide “a dangerous bleach” during the COVID pandemic and pursued criminal enforcement against people promoting its use. Carr and Liester argue that label was based on high-dose misuse, not on the low-dose therapeutic protocols practitioners are actually using.

“The FDA during the COVID pandemic labeled chlorine dioxide a dangerous bleach. Now, this was based on very high doses being misused, not on the low doses that have been demonstrated to be safe.” — Mitchell Liester

The safety data at low doses tells a different story:

  • The EPA established a no-observed-adverse-effect level of 3 mg/kg/day for oral chlorine dioxide
  • Phase I and II clinical trials for ALS confirmed that IV sodium chlorite at doses up to 3.2 mg/kg/day was safe and well-tolerated, with no serious adverse events
  • Millions of people consume low-dose chlorine dioxide daily in municipal drinking water
  • In these three veterinary cases, no adverse effects across enema, oral, and intratumoral routes over treatment periods ranging from 10 days to 8 months

Calling this compound “a dangerous bleach” while millions drink it daily is, as the authors put it, like labeling chemotherapy a poison based solely on high-dose toxicity.

Why the Evidence Stays Thin

If the safety data is there and practitioners are already using it, why does the evidence base remain so limited?

The answer is structural. Chlorine dioxide cannot be patented. That means no pharmaceutical company has a financial incentive to fund the controlled trials that regulators require for approval. Regulators prohibit its therapeutic use because those trials don’t exist. And the prohibition makes it harder for researchers to generate the data that would justify lifting it.

“This compound is not patentable, and therefore it’s unlikely that pharmaceutical companies will want to fund further research.” — Mitchell Liester

(See top link for article and video)

________________

For more:

Category:

Lyme, Malaria, research, Treatment

Vineyard Gazette: Scientists Study Martha’s Vineyard to Get to Root of Chronic Lyme

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/34959511

Vinyard Gazette: Scientists Study Martha’s Vineyard to Get to Root of Chronic Lyme

Carl TuttleHudson, NH, United States

Jul 13, 2026

God forbid we find better antimicrobials for treating Lyme disease because that would give the public an excuse not to take the Lyme vaccine soon to be released!!!

—– Forwarded Message —–
From: CARL TUTTLE <runagain@comcast.net>
To: egenter@vineyardgazette.com <egenter@vineyardgazette.com>; bill@vineyardgazette.com <bill@vineyardgazette.com>; news@vineyardgazette.com <news@vineyardgazette.com>
Cc: linden.hu@tufts.edu <linden.hu@tufts.edu>; cseguin@partners.org <cseguin@partners.org>; jayanta.bhattacharya@nih.hhs.gov <jayanta.bhattacharya@nih.hhs.gov>; Stephanie.Haridopolos@hhs.gov <stephanie.haridopolos@hhs.gov>; kalachakra108@aol.com <kalachakra108@aol.com>; kbliegnermd@optonline.net <kbliegnermd@optonline.net>
Sent: Tuesday, June 30, 2026 at 02:26:37 PM EDT
Subject: Vinyard Gazette: Scientists Study Martha’s Vineyard to Get to Root of Chronic Lyme

Vinyard Gazette
Scientists Study Martha’s Vineyard to Get to Root of Chronic Lyme
https://vineyardgazette.com/news/2026/06/28/scientists-study-marthas-vineyard-get-root-chronic-lyme
By Ethan Genter June 28, 2026

Excerpt:
“We don’t really have any idea,” said Dr. Linden Hu, an infectious disease specialist at Tufts who is helping lead the research. “We had the same hypotheses we had 30 years ago with no clear .
“People are recruited when they have the tell-tale rash – one of the earliest signs of Lyme disease.”

Vineyard Gazette
Edgartown, MA
Attn: Ethan Genter, News Editor

Dear Ethan,
Please see the following eleven articles published in the peer-reviewed literature on dapsone combination therapy for Lyme disease and the MSIDS model. Does Dr. Hu really not know about them, or dismisses Dr. Horowitz’ results because it’s not based on a randomized trial? It is interesting that Tufts received millions of dollars of research money from the NIH and Horowitz couldn’t get a 250k grant approved for a randomized, multicenter trial. More on that found here:

Dr. Jay Bhattacharya; Fund Dr. Richard Horowitz’ R34 NIH grant on Dapsone treatment for Lyme disease
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/34365550

As for Hu’s research, it is focusing on the acute or early stage of the disease while patients who are the sickest went years or decades before obtaining a diagnosis ignoring the late-stage Lyme epidemic seen all across this nation. What academic discipline would Hu encounter if he focused on better antimicrobials???
11 Dapsone Articles on The Effective Treatment of Chronic LD & Associated Co-infections Including Bartonella: As of April 2026
Horowitz, R. Improving biomarkers of inflammation including phosphorylated tau in a patient with chronic Lyme disease/post-treatment Lyme disease syndrome using dapsone combination therapy: A case study and literature review. Journal of Alzheimer’s Disease Reports. April 27, 2026. DOI: 10.1177/25424823261445434 https://journals.sagepub.com/…/10.1177/25424823261445434
Horowitz, R.I.; Fallon, J.; Freeman, P.R. Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review. Microorganisms 2024, 12, 909. https://doi.org/10.3390/microorganisms12050909
Horowitz, R.I.; Fallon, J.; Freeman, P.R. Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections. Microorganisms 2023, 11, 2301. https://doi.org/10.3390/microorganisms11092301
Horowitz RI, Freeman PR. Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review. Antibiotics. 2022; 11(7):912. https://doi.org/10.3390/antibiotics11070912
https://www.mdpi.com/2079-6382/11/7/912/htm
Horowitz, R.I.; Freeman, P.R. Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review. Antibiotics 2020, 9, 725. https://doi.org/10.3390/antibiotics9110725
Horowitz, R.I., Murali, K., Gaur, G. et al. Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of B. burgdorferi. BMC Res Notes 13, 455 (2020). https://doi.org/10.1186/s13104-020-05298-6
https://bmcresnotes.biomedcentral.com/…/s13104-020
Horowitz, R.I.; Freeman, P.R. Precision Medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1. International Journal of General Medicine 2019:12 101–119
https://www.dovepress.com/precision-medicine
https://www.ncbi.nlm.nih.gov/pubmed/30863136
https://www.ncbi.nlm.nih.gov/pubmed/30863136
Horowitz, R.I.; Freeman, P.R. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2. Healthcare 2018, 6, 129.
https://www.ncbi.nlm.nih.gov/pubmed/30400667
Horowitz RI, Freeman PR (2016) Are Mycobacterium Drugs Effective for Treatment Resistant Lyme Disease, Tick-Borne Co-Infections, and Autoimmune Disease?. JSM Arthritis 1(2): 1008.
Horowitz RI, Freeman PR (2016) The Use of Dapsone as a Novel “Persister” Drug in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome. J Clin Exp Dermatol Res 7: 345. doi:10.4172/2155-9554.1000345
Tardo AC, McDaniel CE and Embers ME (2023). Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease. Front. Microbiol. 14:1293300. doi: 10.3389/fmicb.2023.1293300
https://www.frontiersin.org/…/fmicb.2023.1293300/full
Dapsone documentary 2024:
https://drtalks.com/…/discover-healing-18-dapsone…/
Dapsone documentary 2025:
https://drtalks.com/…/dapsone-documentary-9-stories-of
Dr. H Podcast with Dr Alain Mass and Dr Charlie Bizilj on The Success of Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease. May 21, 2025
https://us06web.zoom.us/…/TSVaYe6azIti
Passcode: &0yqten0
Dr. Horowitz has a new book and website, which has the 2000+ scientific references in Ending Chronic Illness listed on the site for review.
https://cangetbetter.com/

Respectfully Submitted,
Carl Tuttle
Independent Researcher
Hudson, NH
Cc:
-Dr. Linden Hu, Professor of Immunology at Tufts Medical School
-Claire Seguin, DNP, President and Chief Operating Officer of Martha’s Vineyard Hospital
-Bill Eville, Editor Vinyard Gazette
-Stephanie E. Haridopolos, MD, DABFM Principal Deputy Assistant Secretary for Health
-Jay Bhattacharya, Director of the National Institutes of Health
-Dr. Richard Horowitz, MD Board certified internist in private practice in Hyde Park, New York
-Dr. Kenneth B. Liegner Board Certified Internist with additional training in Pathology and Critical Care Medicine, practicing in Pawling, New York.
Paralyzed by Lyme, they were helped with combo treatments (please read!!!)
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/31772769

Sign this petition

Category:

Activism, Lyme, research, Treatment, vaccines

The Emergency That Will Not Die: Kill the Prep Act

https://popularrationalism.substack.com/p/the-emergency-that-will-not-die-do?

The Emergency That Will Not Die: Do Not Relent

HHS Begins Cutting the COVID EUA Knot. The PREP Act Liability Wall Still Stands. Tell Your Legislators: Tear Down This Wall.

James Lyons-Weiler, PhD

Jul 01, 2026

HHS announced today that Secretary Kennedy signed determinations terminating the COVID-19 EUA declarations for drugs and biological products and for medical devices, because HHS determined that the circumstances justifying those emergency authorities no longer exist. HHS says the drug/biologic declaration ends after a 12-month notice period, while the device declarations end after 180 days.

The Federal Register public-inspection notices give the exact effective dates: June 29, 2027 for COVID-19 drugs and biological products, and December 26, 2026 for the three device declarations covering in vitro diagnostics, personal respiratory protective devices, and other medical devices.

This is an essential first step toward reversing the regulatory capture by Pharma over public health, medicine and our bodies.

The COVID emergency did not merely authorize medical products. It reorganized accountability. Here’s how, and what comes next.

The Public Readiness and Emergency Preparedness Act, the PREP Act, created the liability architecture. The statute granted a covered person immunity from suit and liability under federal and state law for claims of loss caused by, arising out of, relating to, or resulting from administration or use of a covered countermeasure when HHS issues a declaration for that countermeasure. The same statutory section extends that immunity to claims causally related to design, development, clinical testing, manufacture, labeling, distribution, marketing, promotion, sale, purchase, donation, dispensing, prescribing, administration, licensing, or use. That is not ordinary product regulation. That is an extraordinary legal shield.

COVID policy went askew because the federal government placed emergency countermeasures inside that shield, then allowed public agencies, employers, hospitals, universities, schools, pharmacies, and media institutions to behave as though the shielded products had entered civic life under ordinary conditions. They had not. The public encountered campaigns, recommendations, employment pressure, access restrictions, and moral messaging. The manufacturers and administrators operated inside a liability regime that ordinary medical products do not enjoy.

That is the first distortion: the burden moved downward. Manufacturers received insulation. Program planners received insulation. Administrators received insulation. Injured individuals moved into a narrow administrative channel, and they carried the burden they never agreed to carry.

The PREP Act also created the covered-countermeasure compensation process. The statute establishes a fund for eligible individuals with covered injuries directly caused by administration or use of a covered countermeasure, but the process does not replicate ordinary civil litigation. HRSA’s own comparison of the Countermeasures Injury Compensation Program and the National Vaccine Injury Compensation Program states that CICP has a one-year filing deadline, does not pay attorneys’ fees or costs, resolves requests through an administrative process, allows one administrative reconsideration step, and permits no judicial appeal. VICP proceeds through the U.S. Court of Federal Claims, uses Special Masters or judges, and permits judicial appeal.

That is the second distortion: injury claims did not enter the legal system the public imagines when it hears the word “compensation.” They entered CICP…… (See link for full article)

The third distortion came from the Emergency Use Authorization structure.

FDA states that an EUA declaration under section 564 of the Federal Food, Drug, and Cosmetic Act differs from and does not depend on a public-health emergency declaration under section 319 of the Public Health Service Act. FDA also states that an EUA may remain in effect beyond the end of the section 319 public-health emergency if the statutory conditions remain satisfied. If the HHS Secretary terminates an EUA declaration, EUAs issued under that declaration cease to be effective, with limited transition exceptions, and FDA may no longer issue EUAs for products covered by that declaration.

That separation turned emergency law into a maze. The public-health emergency could end while the emergency product channel continued. The visible emergency could recede while the legal machinery remained in place. The public could hear that the crisis had ended while COVID products, tests, devices, and therapeutics continued through emergency pathways.

With the termination of the EUA, HHS has now started cutting that maze apart. This is not a small administrative cleanup. It is the first formal admission that the COVID emergency-use structure no longer fits the regulatory facts.

Here is the policy indictment: the government allowed emergency authority to outlive the emergency conditions that justified it.

__________________

Important excerpt:

The PREP Act wall still stands. The twelfth PREP Act amendment extended the time period of PREP Act coverage through December 31, 2029, and it expressly extends liability protections for specified covered countermeasures and qualified persons, including licensed pharmacists, pharmacy interns, and qualified pharmacy technicians administering COVID-19 vaccines to individuals aged three and above through December 31, 2029.

That is the remaining knot.

Weiler recommends a full HHS audit of every vestige of the COVID ’emergency,’ including the liability cord the PREP Act still allows.

Weiler also shows how surfaced NIH emails reveal superficial comprehension of how outbreaks become epidemics and pandemics, and it has nothing to do with transmission – it began with institutions and future trigger for financing, platforms, boards, intellectual property, liability shields, and global coordination. It was all about apparatus.

For more:

For an excellent read by France’s long-time vaccine policy chief, Professor Christian Perronne, on the stupidity of the entire COVID debacle from a scientific perspective: https://madisonarealymesupportgroup.com/2021/08/19/covid-policy-is-completely-stupid-unethical-states-frances-vaccine-policy-chief-who-was-recently-fired-for-stating-this/

Category:

Activism, Treatment, vaccines, Viruses